Photobiomodulation for Cancer-Related Cognitive Impairment
- Conditions
- Cancer-related Cognitive Impairment
- Registration Number
- NCT05855694
- Lead Sponsor
- Arash Asher, MD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria:<br><br> - Adults = 18 years<br><br> - Previous diagnosis of stage I-III non-central nervous system solid tumor malignancy,<br> Hodgkin, or Non-Hodgkin lymphoma<br><br> - Completed cancer treatment (chemotherapy and/or radiation) more than 6 months ago<br> but less than 5 years ago (Current concurrent endocrine therapy, anti-HER-2 therapy<br> allowed, or other stable maintenance therapies (such as rituximab) will be allowed.<br><br> - Self-reported cognitive complaints (score = 54 on the Functional Assessment of<br> Cancer Therapy-Cognition, Version 3, Perceived Cognitive Impairment subscale)<br><br> - Written informed consent obtained from subject and ability for subject to comply<br> with the requirements of the study.<br><br> - Ability to read, write and understand either English OR Spanish.<br><br>Exclusion Criteria:<br><br> - Current pregnancy or nursing status<br><br> - Current use of Photobiomodulation (PBM) (for any reason)<br><br> - A lifetime history of any brain tumor or central nervous system metastasis<br><br> - Previous use of intrathecal chemotherapy, chimeric antigen receptor treatment<br> (CAR-T), or stem cell/marrow transplant<br><br> - Known history of other neurological conditions involving impaired cognitive function<br> (such as Alzheimer's Disease and related dementias, Parkinson's Disease, or Multiple<br> Sclerosis).
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive Symptoms
- Secondary Outcome Measures
Name Time Method Cognitive Abilities;Quality of Life;Depression;Anxiety